Ads
related to: carboplatin chemotherapy- nmCRPC Treatment Option
31% Risk of Death Decrease
Visit The Patient Site.
- Dosing & Administration
View Recommended Dosage & Learn
About Drug Interactions Here.
- Clinical Information
Read About A Double-Blind, Placebo-
Controlled, Randomized Study.
- mHSPC Treatment Option
32% Risk of Death Decrease
Visit The Patient Site.
- Downloadable Resources
Resources For Physicians & Patients
Available On The Site To Download.
- Patient Profiles
Explore Patient Profiles To Assess
A Treatment Option.
- nmCRPC Treatment Option
Search results
Cullinan Therapeutics announces success for zipalertinib as combo therapy
Clinical Trials Arena via Yahoo Finance· 21 hours agoEGFR is overexpressed in tumour cells and involved in cell proliferation. Johnson & Johnson’s...
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
Pharmaceutical Technology via Yahoo Finance· 3 days agoCompared to the chemotherapy control, ivonescimab plus...
ASCO 2024: AbbVie flexes early success of ADC pipeline in solid tumours
Clinical Trials Arena via Yahoo Finance· 23 hours agoThe therapy was evaluated as a monotherapy and in combination with AbbVie’s investigative programmed...
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 4 days agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 12 hours agoLate-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with ...
MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side...
Valley City Times Record· 2 days agoThe PRIMED study found a way to reduce treatment-related side effects among participants, decreasing...
Merck’s KEYTRUDA shows survival benefits in Phase III TNBC trial
Clinical Trials Arena via Yahoo Finance· 6 days agoParticipants were assigned in a 2:1 ratio to receive either KEYTRUDA with chemotherapy or a...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
Ram Page· 3 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...
Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumors
Medical Xpress· 11 hours agoThe studies were featured in an oral abstract session highlighting the development of new molecularly targeted agents. Preliminary data from a Phase I study evaluating the novel antibody-drug ...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Morningstar· 3 days agoInvestigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark Phase 3 MARIPOSA data featured in an oral presentation at ASCO CHICAGO
Ads
related to: carboplatin chemotherapy